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Abstract 
Heterogeneity of mesenchymal stem cells (MSCs) influences the cell therapy outcome and the application 
in tissue engineering. Also, the application of subpopulations of MSCs in cartilage regeneration remains 
poorly characterized. CD146+ MSCs are identified as the natural ancestors of MSCs and the expression 
of CD146 are indicative of greater pluripotency and self-renewal potential. Here, we sorted a CD146+ 
subpopulation from adipose-derived mesenchymal stem cells (ADSCs) for cartilage regeneration. 
Methods: CD146+ ADSCs were sorted using magnetic activated cell sorting (MACS). Cell surface 
markers, viability, apoptosis and proliferation were evaluated in vitro. The molecular signatures were 
analyzed by mRNA and protein expression profiling. By intra-articular injections of cells in a rat 
osteochondral defect model, we assessed the role of the specific subpopulation in cartilage 
microenvironment. Finally, CD146+ ADSCs were combined with articular cartilage extracellular matrix 
(ACECM) scaffold for long term (3, 6 months) cartilage repair.  
Results: The enriched CD146+ ADSCs showed a high expression of stem cell and pericyte markers, 
good viability, and immune characteristics to avoid allogeneic rejection. Gene and protein expression 
profiles revealed that the CD146+ ADSCs had different cellular functions especially in regulation 
inflammation. In a rat model, CD146+ ADSCs showed a better inflammation-modulating property in the 
early stage of intra-articular injections. Importantly, CD146+ ADSCs exhibited good biocompatibility with 
the ACECM scaffold and the CD146+ cell-scaffold composites produced less subcutaneous inflammation. 
The combination of CD146+ ADSCs with ACECM scaffold can promote better cartilage regeneration in 
the long term. 
Conclusion: Our data elucidated the function of the CD146+ ADSC subpopulation, established their 
role in promoting cartilage repair, and highlighted the significance of cell subpopulations as a novel 
therapeutic for cartilage regeneration. 










Articular cartilage, lacking blood vessels, 
lymphatic vessels, and nerves, is not subjected to 
systemic regulation [1]. Cartilage is susceptible to 
damage, and acute lesions without proper treatment 
may result in post-traumatic osteoarthritic 
progression [2, 3]. Traditionally, bone marrow 
stimulating procedures, including abrasion, 
subchondral drilling, and microfracture techniques, 
can mobilize progenitor cells from the subchondral 
bone to promote cartilage repair [4-6]. However, 
hyaline repair tissue cannot be consistently induced, 
and most often it does not suffice to fill the entirety of 
the defect. Currently, autologous chondrocyte 
implantation is used in clinical practice [7], but issues 
of limited availability, de-differentiation, and 
functional loss during in vitro culturing limit its 
application [8]. Stem cells, because of their high cell 
viability, and multilineage differentiation capacity, 
are therefore being investigated as alternative cell 
sources for cartilage regeneration [9-12]. 
Research on stem cell-based tissue engineering 
has until now mostly concentrated on harvesting 
mesenchymal stem cells (MSCs) from different 
sources, such as bone marrow [13, 14], adipose tissue 
[15], synovium [16], the bloodstream [17], umbilical 
cord/Wharton’s jelly [18], amniotic fluid [19] and the 
amnion [20], for exploring their self-renewal and 
differentiation capacities and their application in in 
vivo cartilage repair. However, MSCs are a heterogen-
eous population, which cannot be identified and 
isolated using single surface markers [21, 22], and 
therefore MSC-based clinical trial outcomes vary [21]. 
Hence, the cellular heterogeneity of MSCs affects the 
treatment outcome. In this context, the use of specific 
subpopulations of MSCs in tissue regeneration is an 
emerging idea and represents an innovative 
approach. 
CD146, also known as MUC18, MCAM, 
Mel-CAM, or S-Endo1, is a transmembrane 
glycoprotein and an adhesion molecule of the 
immunoglobulin (Ig) superfamily [23, 24]. CD146 was 
initially known as an endothelial biomarker and a 
marker for melanoma progression [25]. Later, it was 
also recognized as a marker for pericytes [24, 26], 
which have been identified as the natural ancestors of 
MSCs [27, 28]. In human tissues, CD146+ cell was 
regarded as the mural cells of blood micro vessels [29, 
30]. Previous reports also showed that CD146 was 
associated with cell migration and self-renewal [31, 
32]. Hagmann et al. found that CD146+ bone marrow 
MSCs (BMSCs) increased GAG/DNA content after 
enrichment [33]. Wu et al. reported that a CD146+ 
subpopulation from human umbilical cord cells could 
treat arthritis and provide an anti-inflammatory 
protective microenvironment by suppressing IL-6 
[34]. Su et al. showed that CD146+ chondroprogenitors 
expressed higher levels of an MSC-specific marker 
and had better chondrogenic differentiation capacity 
[35]. Thus, we hypothesized that CD146+ 
subpopulations have the potential to promote better 
cartilage repair.  
For clinical applications, sorting CD146+ cells 
from adipose-derived MSCs (ADSCs) has many 
advantages. ADSCs are maintainable in vitro for 
longer times than BMSCs and exhibit stable 
population doubling with higher proliferation and 
lower senescence rates. Fewer ADSC passages are 
required to obtain adequate cell numbers. hADSCs 
can be derived from lipoaspirate, which can be 
harvested through tumescent abdominal liposuction 
techniques. A sufficient number of cells can be 
obtained in one attempt which avoids the morbidity 
associated with harvest [10, 36]. A recent study 
compared the differences of ADSCs and BMSCs at 
single- and bulk-cell levels on the treatment of 
osteoarthritis, they found ADSCs as a more stable and 
controllable stem cell source, was more adaptable to 
surviving in the hypoxic articular cavity niche, and 
exhibited superiority in regulating inflammation [37]. 
In this study, we report a CD146+ MSC 
subpopulation-based cartilage tissue engineering 
strategy. The CD146+ subpopulation was enriched 
from human ADSCs. Cellular characteristics, inclu-
ding the expression of the surface marker, immune 
character, viability, proliferation gene and cytokine 
expression patterns were identified in vitro. Further, 
the role of the CD146+ subpopulation in the cartilage 
microenvironment was explored in vivo. To provide a 
more suitable microenvironment for cell 
transplantation, we also developed an articular 
cartilage extracellular matrix (ACECM) cell-scaffold 
composite and investigated its biocompatibility and 
its role in repairing cartilage defects. We successfully 
identified and isolated CD146+ subpopulations from 
hADSCs, investigated their cytological functions, and 
established their role in cartilage regeneration. 
Methods  
hADSC culture 
Human adipose-derived mesenchymal stem 
cells (hADSCs) at passage 4 were provided by the 
National Cell Bank for Tissue Engineering (Zhejiang, 
China). hADSCs were plated in growth medium 
consisting of Dulbecco’s Modified Eagle Medium/ 
Fisher12 (DMEM/F12) medium (10% fetal bovine 
serum, 1% penicillin-streptomycin added), followed 
by incubation in a humidified incubator at a 
temperature of 37 °C. Cells were harvested when they 





reached ~80% confluence using 0.25% trypsin in 
ethylenediaminetetraacetic (EDTA; Invitrogen). 
Isolation of CD146+ cells from hADSCs 
CD146+ cells were isolated from a suspension of 
passage 5 hADSCs by magnetic activated cell sorting 
(MACS) using anti-CD146 magnetically labeled 
antibodies (catalog 130-093-596, Miltenyi Biotec) 
(Figure 1A). 
Flow cytometry 
A 100-mL aliquot of hADSCs or freshly sorted 
CD146+ cells suspension (1×106/mL) was transferred 
to the test pipe. Cells were stained with anti-human 
antibodies against the following cell surface markers: 
CD34-PE (BD Pharmingen), CD45-FITC (BD 
Pharmingen), CD73-PE (BD Pharmingen), CD90-FITC 
(BD Pharmingen), CD105-PE (BD Pharmingen), 
CD146-PE (BD Pharmingen), and HLA-DR-FITC (BD 
Pharmingen). The cells were incubated in the dark for 
30 min, collected on a FACS Calibur flow cytometer, 
and the results were analyzed using Cell-Quest for 
Macintosh Software. 
Western blotting 
Total proteins were extracted from hADSCs and 
freshly sorted CD146+ cells using RIPA buffer with 
PMSF. After quantifying the protein concentration 
using a BCA protein assay kit, proteins were subjected 
to SDS-PAGE and transferred to a PVDF membrane. 
The membrane was incubated with primary 
antibodies against the following proteins: HLA-1 
(1:1000; Abcam), MHC-II (1:10,000; Abcam), CD40 
(1:500; Abcam), CD80 (1:500; Abcam), CD86 (1:5000; 
Abcam), NG2 (1:5000; Novus Biologicals), PDGFR-β 
(1:1000; Abcam), RGS5 (1:1000; Novus Biologicals), 
and GAPDH (1:10,000). Subsequently, the membrane 
was washed with Tris-buffered saline (TBS) 
containing 0.05% Tween-20 and incubated with an 
anti-mouse or an anti-rabbit HRP-conjugated 
secondary antibody. The antigen–antibody reaction 
was visualized using enhanced chemiluminescence 
assay (Western Luminescent Detection Kit) and 
documented using Gel Doc (Bio-Rad). 
Immunocytochemical and 
immunofluorescence staining 
For immunocytochemical staining, cells were 
fixed with 4% paraformaldehyde (PFA) for 20 min at 
room temperature, treated with methanol for 10 min, 
washed with PBS, permeabilized with 0.25% Triton 
X-100 in PBS for 20 min, and blocked with 5% goat 
serum in 0.25% Triton X-100 in PBS for 20 min. Next, 
cells were incubated with anti-HLA Class I (Abcam, 
ref. ab23755) and anti-MHC-II (Abcam, ref. ab157210) 
at 4°C overnight. The immunodetection was 
performed using DAB (MXB biotechnologies), 
following the manufacturer’s instructions. Cells were 
viewed with an Olympus BX51 light microscope 
(Olympus, Tokyo, Japan). The images were captured 
using an Olympus CCD DP71 (Olympus). 
 
 
Figure 1. Overview of experimental design. (A) MACS enrichment of CD146+ ADSCs. (B) Comparison of cytological characteristics between ADSCs and CD146+ ADSCs 
in vitro. CD146+ ADSCs retained good viability, proliferation ability, and stem cell character after sorting. CD146+ ADSCs also showed pericyte characteristics, better immune 
properties, and inflammation regulation ability. (C) A schematic illustration of the intra-articular injection of CD146+ ADSCs in rats. (D) Flow chart of the preparation of the 
cell-scaffold composite for long term cartilage repair in rabbits. 





For immunofluorescence staining, cells were 
fixed with 4% PFA for 20 min at room temperature, 
treated with methanol for 10 min, washed with PBS, 
permeabilized with 0.25% Triton X-100 in PBS for 20 
min, and blocked with 5% goat serum in 0.25% Triton 
X-100 in PBS for 20 min. Subsequently, cells were 
incubated with anti-CD146 (Abcam), anti-PDGFR-β 
(Abcam), anti-RGS5 (Novus Biologicals), or 
anti-NG2/MCSP (Novus Biologicals) at 4°C 
overnight. On the the next day, cells were washed and 
incubated with secondary antibody in 5% goat serum 
for 1 h at room temperature. Cells were 
counterstained with a 1:1000 dilution of DAPI to label 
the nuclei and viewed with an Olympus BX51 light 
microscope (Olympus, Tokyo, Japan). The images 
were captured by using an Olympus CCD DP71 
(Olympus). 
Quantitative real-time PCR 
Total RNA from hADSCs and freshly sorted 
CD146+ cells was isolated using Trizol following the 
manufacturer’s instructions (Sigma (T9424)). The 
cDNA was synthesized using the SuperScript TM III 
First-strand synthesis system for RT-PCR, cat. No: 
18080-051 (Invitrogen). Quantitative RT-PCR was 
performed using the Power SYBRgreen PCR Master 
Mix (ABI, P/N: 4367659). Primers were shown in 
Table S1. The PCR cycling condition included an 
initial denaturation at 95°C for 2 min, 40 cycles of 95°C 
for 15 s, 58°C for 15 s, and 72°C for 35 s, and a final 
extension at 72°C for 5 min. The results were analyzed 
using Bio-Rad iQ5 optical system software. 
Cell proliferation evaluation by Cell Counting 
Kit-8 (CCK-8) 
Cells were seeded at 3000 cells per well in a 
96-well plate and cultured in a humidified incubator 
at a temperature of 37°C. The relative cell number was 
determined using CCK8 by OD (absorbance) value 
after 1, 3, and 5 days of culturing, following the 
manufacturer’s instructions. The morphology of cells 
on was observed by phase-contrast microscopy 
(Olympus, BH-2). 
Apoptosis and viability analysis 
The hADSCs and freshly sorted CD146+ cells 
were trypsinized using 0.25% trypsin-EDTA and 
harvested by centrifugation. Apoptosis of ADSCs and 
CD146+ cells was detected using Muse Count & 
Viability Kit (MCH100102). Briefly, cells were 
incubated with Muse Annexin V & Dead Cell reagent 
for 20 min at room temperature as per with the 
manufacturer’s instructions and analyzed using 
Merck&Millipore Muse Cell Analyzer. Viability of 
ADSCs and CD146+ cells was determined using Muse 
Annexin V & Dead Cell Kit (MCH100105). Cell 
suspension and Muse Count & Viability reagent were 
added to each tube, incubated for 5 min at room 
temperature, and analyzed using the Merck& 
Millipore Muse Cell Analyzer. 
Microarray analyses 
Total RNA was isolated from hADSCs and 
freshly sorted CD146+ cells using Trizol reagent and 
purified with mirVana mRNA Isolation Kit (Ambion, 
Austin, TX, USA). The RNA integrity was determined 
using the RNA 6000 Nano Lab-on-a-Chip kit and the 
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, 
CA, USA). Only RNA extracts with RNA integrity 
number values >6 were used for further analysis. 
Gene expression analyses were performed using the 
Agilent human mRNA Array. The array data were 
analyzed with the help of Capitalbiotech for data 
summarization, normalization, and quality control by 
using the GeneSpring software V13 (Agilent). To 
select the differentially expressed genes, we used 
threshold values of ≥2- and ≤0.5-fold change and a 
Benjamini–Hochberg-corrected P-value of 0.05. The 
data were log(2)-transformed and median-centered by 
genes using the Adjust Data function of CLUSTER 3.0 
software. The data were further analyzed with 
hierarchical clustering with average linkage [38]. Tree 
visualization was performed by using Java Treeview 
(Stanford University School of Medicine, Stanford, 
CA, USA). Gene ontology (GO) pathway enrichment 
analysis was performed by WEGO (http://wego. 
genomics.org.cn/cgi-bin/wego/index.pl). 
Cytokine analysis 
The ADSCs and CD146+ cells were lysed and 
quantified. The lysates were analyzed for chemokines 
and growth factors (80 cytokines in total) using a 
RayBio® Human Cytokine Antibody Array G5 
(RayBiotech, USA), following the manufacturer’s 
instructions. Data were analyzed using GenePix Pro 
6.0. 
Rat osteochondral defect model and 
histological examination 
Eight-week-old SD rats with a mean weight of 
220 ± 20 g were used in this study (Figure 1C). Using 
an electric drill, osteochondral defects (1.5 mm 
diameter and 1 mm depth) were created through both 
the chondral and the subchondral bone layer of the 
patellar trochlear groove in their right legs. The joint 
capsule and the overlying muscle were closed with a 
suture. All rats were randomly allocated into four 
groups: defects with intra-articular injections of PBS 
(negative control), defects with intra-articular 
injections of ADSCs (1×105), defects with 
intra-articular injections of CD146+ cells (1×105), and 
the sham-operated group. The knee joint samples 





were collected 2 weeks after the operation. For 
histological examination, the samples were stained 
with immunohistochemistry staining of HLA-ABC 
(Abcam, 1:100), IL-1β (Abcam, 1:100), IL-6 (Abcam, 
1:100), IL-10 (Abcam, 1:100), H&E, Safranine O, and 
Toluidine Blue. 
Multiplex cytokine assay 
Areas of the cartilage and subchondral bone with 
defects were selected. Inflammatory cytokines present 
in the cartilage and subchondral bone samples were 
detected following the manufacturer’s instructions 
(RayBiotech, USA). Data were analyzed using 
GenePix Pro 6.0. 
Fabrication of cell-scaffold composites 
The synthesis of the Production of the ACECM 
scaffold was described previously [39]. The diameter 
of the scaffolds was 3.5 mm and the height of the 
scaffold was 2 mm. A total number of 5×105 hADSCs 
or freshly sorted CD146+ cells were seeded into 
ACECM scaffolds and cultured in DMEM/F12 for 3 
days. 
Scanning electron microscopy 
After being in cluture for 3 days, the 
microarchitecture of cell-scaffold composites was 
analyzed using the scanning electron microscopy 
(SEM) (S-2600N, Japan). Cell-scaffold composites, 
after de-hydrating in a graded ethanol series, were 
dried in a critical point dryer and coated with 
gold-palladium (EMS850X, USA). 
Live/dead staining and confocal microscopy for 
cell viability/growth 
After being in culture for 3 days, the viability 
and growth of cells in the scaffold were assessed by 
live/dead staining following the manufacturer’s 
guidelines (Sigma). The viable cells were labeled in 
green and dead cells were labeled in red. Live and 
dead cells were visualized and scored using 
fluorescence imaging and confocal microscopy (Leica 
Microsystems DM6000B–SP57CS). 
In vivo biocompatibility and degradability 
Cell-scaffold composites were subcutaneously 
embedded into the back skin of New Zealand white 
rabbits (~2.0 kg) to evaluate their degradation and 
biocompatibility. At 1, 2, and 4 weeks after 
implantation, rabbits were euthanized, and 
photographs of the remaining cell-scaffold composites 
under the skin were taken. H&E staining was also 
carried out to evaluate the histological changes. 
Immunofluorescence staining of HLA-ABC (Abcam) 
was performed to evaluate human cell persistence 
overtime. 
In vivo surgical procedure of full-thickness 
rabbit cartilage defect repair 
Sixty healthy New Zealand white rabbits (~2.0 
kg) were employed for the in vivo cartilage defect 
repair experiments (Figure 1D). The region of interest 
was shaved and aseptically prepared for operation. 
Using an electric drill, a cartilage defect (3.5 mm 
diameter and 2 mm depth) was created through the 
chondral layers of the patellar trochlear groove in 
their right legs. The defects of the experimental group 
were implanted with ACECM scaffold, ADSCs & 
ACECM scaffold composites, and CD146+ 
subpopulation & ACECM scaffold composites. The 
defects of the negative control group received no 
treatment. A sham-operated group was also included. 
Each group consisted of 12 healthy New Zealand 
white rabbits. Animals were housed individually and 
given penicillin for 7 days following the operation. All 
rabbits were euthanized at the pre-determined time 
points (3 or 6 months). The knee joints were collected 
for further evaluation. 
X-ray and magnetic resonance imaging 
The samples were first assessed using an X-ray 
scanner (Faxitron, USA). Subsequently, the magnetic 
resonance imaging (MRI) scans were taken using a 7.0 
T Bruker Biospec system (Bruker Biospec, Germany). 
T2-weighted spin-echo images with fat suppression 
were obtained in the sagittal, frontal, and transverse 
planes. All images were scored independently 
following the Score System for MRI Evaluation [40] 
(Table S2). 
Macroscopic observations 
The cartilage defect area in the femoral condyles 
and the tibial plateau was observed and 
photographed. All images were scored independently 
by an experienced researcher specialized in 
musculoskeletal disease and blinded to the group 
assignments, following the International Cartilage 
Repair Society (ICRS) macroscopic evaluation 
guidelines (Table S3). 
Histology and histomorphometry 
For histological examination, tissue samples 
were fixed in 4% PFA, de-calcified in EDTA, and 
prepared for paraffin-embedded sections. The 
regenerated cartilage was sectioned into 6-μm slices 
and stained with H&E, Safranin-O, Toluidine blue 
and Sirius Red following the manufacturer’s 
protocols. All images were scored independently by 
an experienced researcher specialized in 
musculoskeletal disease and blinded to the group 
assignments according to the ICRS histological 
assessment scale (Table S4). 






All quantitative data were analyzed using SPSS 
version 22.0 (SPSS, Chicago, IL, USA) and reported as 
the mean ± standard error of the mean. Student’s t-test 
or one-way analysis of variance (one-way ANOVA), 
followed by the Bonferroni multiple comparison test, 
was performed for normally distributed data. A value 
of P < 0.05 was considered to indicate a statistically 
significant difference. 
Study approval 
All animal experiments were performed strictly 
following the standards for the care and use of 
laboratory animals and were approved by the 
Institutional Animal Care and Use Committee of the 
Chinese PLA General Hospital. 
Results 
Enriched CD146+ subpopulation retains the 
expression of mesenchymal stem cell and 
pericyte surface markers, and has a better 
immune character 
CD146+ subpopulation was sorted by MACS and 
the expression of stem cell surface markers was 
examined. Similar to hADSCs, CD146+ subpopulation 
expressed the cell surface markers CD73, CD90, and 
CD105, but did not express CD34, CD45, and 
HLA-DR (Figure 2A). After the enrichment, the 
percentage of the CD146+ subpopulation increased 
from 13.48% to 88.12% (Figure 2A). To determine the 
expressions of other pericyte surface markers in 
CD146+ subpopulation, immunofluorescence staining 
and Western blotting were performed (Figure 2B-C). 
As shown by immunofluorescence staining, the 
CD146+ subpopulation co-expressed the other 
pericyte markers NG2, PDGFR-β, and RGS5 (Figure 
2B). Western blotting demonstrated that the 
expression levels of these markers in CD146+ 
subpopulation were higher than those in hADSCs 
before enrichment (Figure 2C). 
We further investigated the immune 
characteristics of the CD146+ subpopulation. The 
expression of MHC determines the matching of 
allografts with hosts. As validated by 
immunocytochemistry and Western blotting, the 
expression of MHC-I was faintly positive in CD146+ 
subpopulation, and was lower than hADSCs before 
sorting (Figure 2D), whereas the expression of 
MHC-II was negative in both ADSCs and the CD146+ 
subpopulation (Figure 2D). CD40, CD80 (B7-1), and 
CD86 (B7-2) are co-stimulatory molecules, which 
interact with CD28 of T-cells and form the second 
signal necessary for T-cell activation. The absence of 
these molecules causes T-cell anergy. No significant 
difference was found in the expression levels of CD40, 
CD80, and CD86 between the CD146+ subpopulation 
and hADSCs as determined by qPT- PCR and 
Western blotting (Figure 2C). IDO, PGE2, IL-10, and 
HGF are molecules that have an immune suppressive 
effect. Although the expression levels of IDO in the 
CD146+ subpopulation were lower than those in 
ADSCs, the expression levels of PGE2 and IL-10 were 
significantly higher in the CD146+ subpopulation 
(Figure S2). 
CD146+ subpopulation retains a high 
proliferation rate and viability after the 
enrichment 
Proliferation capacity of the CD146+ 
subpopulation was examined by morphology 
observation and Cell Counting Kit-8 (CCK-8) assay on 
day 1, 3, and 5(Figure 3A-B). The results showed that 
both ADSCs and CD146+ cells adhered to the surface 
and proliferated well under standard culture 
conditions (Figure 3A). The latent phase and 
logarithmic phase lasted from day 1–3, and the 
stationary phase lasted from day 3–5. No significant 
difference was observed between ADSCs and CD146+ 
subpopulation during the entire period (Figure 3B). 
Cell viability (Figure 3E) and apoptosis (Figure 3C) 
were determined by flow cytometric analysis, and the 
percentages of cells in different stages were calculated 
(Figure 3D, F). The quantitative analysis suggested 
that the CD146+ subset maintained high cell viability 
(over 95%) and a low apoptotic rate after the 
enrichment confirming the good growth properties 
(Figure 3D, F). 
CD146+ subpopulation is distinct from 
hADSCs with a unique molecular signature 
To identify the molecular signature of the 
CD146+ subpopulation, we performed an mRNA and 
protein expression microarray analyses and compared 
the expression profiles of cells before and after 
sorting. In mRNA microarrays, a total of 428 
differentially expressed genes were identified, of 
which 221 genes were up-regulated in CD146+ cells, 
and 208 were downregulated (Figure 4A). Differential 
gene expression was subjected to cluster analysis in 
which biological replicates in each group were 
clustered together (Figure 4A). Differentially 
expressed genes included immune and inflammatory 
genes such as IL6, CXCL2, IL1RL1, IL17RD, IL18, and 
IL26 (Figure 4B). Gene ontology (GO) classification of 
genes by biological processes showed differentially 
expressed genes were involved in multicellular 
organismal processes, such as chemotaxis, wound 
healing, blood vessels, and inflammatory processes 
(Figure 4C). Protein expression of ADSCs and CD146+ 





subpopulation was tested by using antibody 
microarrays. Among 80 chemokines and growth 
factors, 11 differentially expressed proteins were 
identified (Figure 4D). Differentially expressed 
chemokines included immune and inflammatory 
proteins such as IL6, IL12 and IL16. GO classification 
showed that differentially expressed proteins play a 
role in chemotaxis and cell division (Figure 4E-F). The 
combined gene and protein expression results 
indicated that, compared to hADSCs, the CD146+ 
subpopulation was a distinct population and had a 
molecular signature in inflammation functions before 
sorting. 
CD146+ subpopulation reduces inflammation 
of the articular cartilage during the early 
stages of cells injection 
To elucidate the cellular functions in vivo, we 
employed a rat osteochondral defect model obtained 
by intra-articular injections of cells, and formulated 
four groups: defects with intra-articular injections of 
PBS (negative control), ADSCs, and CD146+ 
subpopulation, and the sham-operated group (Figure 
5A). Macroscopic observation showed that the defect 
area could not be totally repaired in two weeks after 
injection in all the groups (Figure 5A). 
Immunohistochemical staining of HLA-ABC specially 
 
 
Figure 2. Surface markers expression and immune characteristics of CD146+ ADSCs before and after MACS enrichment. (A) Flow cytometric analysis of 
MSC-specific surface markers in CD146+ ADSCs and donor-matched ADSCs. CD146+ ADSCs and donor-matched ADSCs were stained for CD34, CD45, CD73, CD90, 
CD105, CD146, and HLA-DR. (B) Immunofluorescence images for CD146 (red), NG2 (green) RGS5 (green) and PDGFR-β (green) in CD146+ ADSCs and donor-matched 
ADSCs. Scale bar: 20 μm. (C) Western blots analysis of MHC-I, MHC-II, CD40, CD80, CD86, NG2, PDGFR-β, and RGS5. MHC-II was not detected in either group. (D) 
Representative images of MHC-I and MHC-II immunohistochemical staining in CD146+ ADSCs and donor-matched ADSCs. Scale bar: 50 μm. 





marked the location of the human cells in the early 
stages of cell implantation (Figure 5B). Results 
showed that both hADSCs and CD146+ subpopulation 
were recruited into the defect area. Histologically, 
although a time span of 2 weeks was too short for the 
repair, intra-articular injections of CD146+ 
subpopulation led to better improvements of the 
quality of osteochondral repair, with less 
inflammatory cells in the boundary between healthy 
tissue and the defected area (Figure 5C). 
Inflammatory cytokines in articular cartilage and 
subchondral bone were further investigated. The 
expression level of IL-6 was significantly higher in the 
hADSCs group, than in the CD146+ group which was 
more similar to that in normal cartilage (Figure 5D). 
Also, the expression of cytokines such as IL-6, IL-1β, 
TNF-α, and IL-10 in the defect area was evaluated 
histologically. Two weeks after the injection, there 
was no significant difference in the expression of 
IL-1β, TNF-α and IL-10, while the expression of IL-6 
was still present on the surface of the defect area in the 
negative control and ADSCs injected groups. Less 
expression of IL-6 was observed in the defect area of 
CD146+ cells injected groups (Figure 5E). Thus, the 
CD146+ subpopulation could reduce inflammation 
during the early stages of cells injection to promote 
cartilage repair. 
CD146+ cell-scaffold composites resulted in 
less subcutaneous inflammation 
Given that CD146+ subpopulation was 
associated with inflammation moderation of the 
cartilage microenvironment during the early stages of 
implantation, we developed ACECM scaffold 
composites for long-term cartilage repair. Same 
numbers of ADSCs and CD146+ subpopulation were 
seeded into ACECM scaffolds and cultured for 3 days 
in vitro (Figure 6A). Macroscopic photographs of the 
three groups are displayed Figure 6B. Scanning 
electron microscopy (SEM) images show the porous 
structure of the ACECM (Figure 6C). The inner walls 
of the evenly distributed pores increase the surface 
area and are suitable for cell adhesion. Both ADSCs 
and CD146+ subpopulation were located in the inner 
wall of the pores, maintained their phenotype, and 
performed normal function after 3 days of culturing 
 
 
Figure 3. Proliferation, apoptosis, and viability of CD146+ ADSCs before and after MACS enrichment. (A) Morphology of CD146+ ADSCs and donor-matched 
ADSCs on day 1, 3, and 5. Cells were cultured at the same density on day 1. Scale bar: 50 μm. (B) Cell proliferation CCK8 assay of ADSCs and CD146+ ADSCs. *P < 0.05, 
pairwise comparisons, Student’s t-test. (C) Apoptosis in ADSCs and CD146+ subpopulation was determined by flow cytometric analysis. (D) The proportion of apoptotic 
ADSCs and CD146+ subpopulation. The proportions of live, early apoptotic, late apoptotic, debris, and dead cells of the CD146+ subpopulation are shown in mean ± standard 
error, ***P < 0.05 by Student’s t-test compared with ADSCs. (E) Viability in ADSCs and CD146+ cells by flow cytometry. (F) Cell viability of ADSCs and CD146+ subpopulation. 
The proportions of live and dead CD146+ cells are shown in the mean ± standard error of the mean, ***P < 0.05 by Student’s t-test compared with ADSCs. 





(Figure 6C). Furthermore, cell viability was measured 
by live/dead cell staining (Figure 6D). Both CD146+ 
subpopulation and ADSCs proliferated and grew well 
in the three-dimensional porous scaffold and most 
viable cells exhibited a uniform distribution (Figure 
6D). These results suggested that the ACECM is not 
toxic to cells and is suitable for cell growth as a useful 
biocarrier material for cartilage repair. 
To further explore the in vivo degradation and 
biocompatibility of the composites, three types of 
cell-scaffold composites (ACECM scaffold, ADSCs & 
ACECM scaffold composites, and CD146+ 
subpopulation & ACECM scaffold composites) were 
subcutaneously implanted into the back skin of 
rabbits, and their role in modulating subcutaneous 
inflammation was investigated (Figure 6E-G). 
 
Figure 4. Gene and protein expression of CD146+ ADSCs before and after MACS enrichment. (A) Heatmap showing transcription expression profiles of ADSCs 
and the CD146+ subpopulation. Differentially expressed genes are shown. Each block represents the relative transcript level of an individual gene. Each column represents the 
profile of an individual group. (B) List of inflammation related genes that were significantly changed in CD146+ cells. (C) GO classification of genes by biological process. (D) 
Cytokine expression of ADSCs and CD146+ cells. Samples were collected from cell protein. Heatmap showing cytokine expression profiles of ADSCs and CD146+ cells. (E) GO 
classification of proteins by molecular function. (F) KEGG pathway of proteins. 





Macroscopic photographs showed that in 1, 2, and 4 
weeks after implantation, cell-scaffold composites 
adhered to a layer of connective tissue and were 
degraded gradually in vivo (Figure 6E). Survival of 
human cells overtime was assessed by 
immunofluorescent staining of HLA-ABC. The results 
showed that ADSCs and CD146+ subpopulation 
retained high survival in 1, 2, and 4 weeks after 
implantation (Figure 6F). As per H&E staining, the 
appearance of inflammatory cells in the first week 
suggested an acute inflammatory response in all three 
groups (Figure 6G). From 2 to 4 weeks, the number of 
inflammatory cells in all three groups decreased 
gradually, reflecting the reduction in inflammatory 
response (Figure 6G). During the entire period of 
observation, the lowest number of inflammatory cells 
was observed in the CD146+ subpopulation & 
ACECM scaffold composite group, confirming that 
this scaffold composite caused the least subcutaneous 
inflammation. 
CD146+ subpopulation in combination with the 
ACECM scaffold improves cartilage 
regeneration 
To verify the role of cell-scaffold composites in 
long term cartilage repair, we implanted them into the 
trochlear groove cartilage defect areas in rabbits. 
X-ray images revealed that there was no osteophyte 
formation and heterotopic ossification in any of the 
five groups during the experimental period (Figure 
7B, Figure S3). At 3 months, new cartilage tissue was 
observed in the ACECM scaffold, ADSCs & ACECM 
scaffold composite, and CD146+ subpopulation & 
ACECM scaffold composite implanted groups by 
high-resolution MRI of the fresh whole knee joints, 
but immature cartilage signal was also present (Figure 
7C). At 6 months, MRI images of the ADSCs & 
ACECM scaffold composite and CD146+ 
 
Figure 5. Role of CD146+ ADSCs in cartilage microenvironment after joint cavity injection. (A) Experimental design for cell transplantation and macroscopic 
analyses of femoral condyle cartilage. Rats were randomly allocated to four groups: defects treated with PBS (negative control), defects treated with ADSCs, defects treated with 
CD146+ cells, and the sham-operated group. At 2 weeks, rats were euthanized, and the distal femora were harvested. (B) Immunohistochemical staining of HLA-ABC. Scale bar: 
100 μm. (C) Histological analysis of the defected area by H&E, Safranin O, and Sirius red staining. Black solid arrows denote the repair interface. Red solid arrows denote the 
depth of the repaired cartilage. HC, host cartilage; D, defect area; RC, repaired cartilage. Scale bar: 100 μm. (D) Analysis of inflammation related cytokine expressions. Results 
represent the mean ± standard error of the mean; the sample number was three. *P < 0.05, **P < 0.01. (E) Immunohistochemical staining of IL-1β, IL-6, IL-10 and TNF-α. Black 
solid arrows denote the positive expression of IL-6 in the repair interface Scale bar: 100 μm. 





subpopulation & ACECM scaffold composite 
implanted groups were almost entirely filled with 
new cartilage tissue better than the ACECM scaffold 
implanted group (Figure 7C). During this period, no 
new tissue was found in the negative control group 
(Figure 7C). MRI score analysis also confirmed these 
results. As shown in Figure 7D, the score in CD146+ 
subpopulation & ACECM scaffold composite 
implanted groups was higher than the other groups at 
3months. At 6 months, both ADSCs & ACECM 
scaffold composite and CD146+ subpopulation & 
ACECM scaffold composites implanted groups 
achieved a high score that was comparable to the 




Figure 6. Fabrication and biocompatibility of cell-scaffold composites. (A) Experimental design of the cell-scaffold composites. ADSCs and CD146+ cells were seeded 
into an ACECM scaffold for 3 days. (B) Macroscopic features of the ACECM scaffold and two cell-scaffold composites. (C) SEM images of the ACECM scaffold and two 
cell-scaffold composites. (D) Live/dead cell analysis for the two cell-scaffold composites. Representative images show dead cells (red), live cells (green), and reconstruction images 
of the two cell-scaffold composites. (E) Photographs of the ACECM scaffold and two cell-scaffold composites subcutaneously implanted in the back of rabbits after 1 week, 2 
weeks, and 4 weeks (the circle indicates the tissue surrounding the scaffold). (F) Immunofluorescent staining of HLA-ABC of the tissues surrounding the implant sites after 1 
week, 2 weeks, and 4 weeks. Scale bar: 50 μm. (G) H&E staining of the tissues surrounding the implant sites after 1 week, 2 weeks, and 4 weeks. Scale bar: 100 μm. 






Figure 7. Radiography assessment of the cartilage in rabbits with cell-scaffold composites treatment. (A) Experimental design for the cartilage repair. The rabbits 
were randomly allocated into five groups: defects without treatment (negative control), defects treated with ACECM scaffold, defects treated with ACECMs and ADSCs, defects 
treated with ACECMs and CD146+ cells, and native group. (B) X-ray images of rabbit knees 3 and 6 months after surgery. (C) MRI of rabbit knees 3 months and 6 months after 
surgery. Red arrow indicates the defected area. The inset in the bottom left corner of each T2 mapping image shows the cartilage labeled by pseudo-color. (D) MRI scoring system 
for evaluation of cartilage repair after 3 and 6 months. Data are expressed as mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.0001. 
 
The entire knee joint was dissected for 
macroscopic evaluation. No apparent inflammation 
and synovial hyperplasia were observed in any of the 
groups during the 6 months (Figure 8A). New 
cartilage generally formed from the edge of the 
defects in the ACECM scaffold and two cell-scaffold 
composite implanted groups from 3 to 6 months 
(Figure 8A). Generally, the shape of the new cartilage 
was better at 6 months compared with 3 months 
(Figure 8A). The regenerated cartilage in the CD146+ 
subpopulation & ACECM scaffold composite 
implanted group was almost similar to native 
cartilage after 6 months (Figure 8A). In the negative 
control group, the defect did not regrow during this 
period (Figure 8A). Consistent with the macroscopic 
results, the International Cartilage Repair Society 
(ICRS) macroscopic evaluation score for regenerated 
cartilage in the CD146+ subpopulation & ACECM 
scaffold composite implanted group was better than 
that of the other groups at 3 and 6 months (Figure 
8B-C, Figure S4). 
The thickness and structure of new cartilage in 
the defected area were visualized histologically 
(Figure 8D-F, Figure S5-8). The chondrocyte-like cells 
were visualized in the defected area in the ACECM, 
ADSCs & ACECM, and CD146+ subpopulation & 
ACECM scaffold composite implanted groups. 
Safranine O and Toluidine Blue stainings were 
negative in the defected area and positive in the 
regenerated hyaline cartilage. Generally, as the repair 
period progressed, the defect was gradually filled 
with new cartilage (Figure 8D-F, Figure S5-8). The 
new cartilage layer was thin in the ACECM scaffold 
implanted group compared with the ADSCs & 
ACECM, and CD146+ subpopulation & ACECM 
scaffold composite implanted groups. However, no 
new cartilage layer was found in the negative control 
group at both 3 and 6 months (Figure 8D-F, Figure 
S5-8). At 6 months, the thickness of the new cartilage 
layer in the CD146+ subpopulation & ACECM 
scaffold composite implanted group was similar to 
that of the native cartilage, with less void space and a 
regular surface. Sirius Red staining also highlighted a 
tangled arrangement of collagen fibers in the CD146+ 
subpopulation & ACECM scaffold composite 
implanted group at 6 months (Figure. 8D-F, Figure 
S6-9). Better regeneration of the cartilage in the 
CD146+ subpopulation & ACECM scaffold 
composites implanted group was also confirmed by 
the International Cartilage Repair Society (ICRS) 
macroscopic evaluation score. 
Discussion 
It has long been known that MSCs comprise a 
heterogeneous population, which impedes their 
application in regenerative medicine [22]. Studies 





found that some subpopulations have enhanced 
capacity for cartilage formation. For example, 
Dickinson et al. reported the subpopulation with the 
receptor tyrosine kinase-like orphan receptor 2 
(ROR2) as a cell surface marker is effective at making 
cartilage. The application of subpopulations is 




Figure 8. Macroscopic and histological evaluation of cartilage repair after cell-scaffold composite treatment. (A) Macroscopic observations of rabbit knees (distal 
femur and tibial plateau) 3 and 6 months after surgery. (B) (C) ICRS scoring system for macroscopic evaluation of cartilage repair after 3 months (B) and 6 months (C). Data are 
expressed as mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.0001. (D) Histological analysis of the cartilage defect after 3 and 6 months by H&E and Sirius Red staining. Black solid 
arrows denote the repair interface. Red solid arrows denote the depth of the repaired cartilage. HC, host cartilage; RC, repaired cartilage. Scale bar: 200 μm. (E) (F) ICRS scoring 
system for histological evaluation of cartilage repair after 3 months (E) and 6 months (F). 
 





As a surface marker expressed by pericytes and 
the smooth muscle cells of blood vessels, CD146 plays 
a critical role in cell adhesion, embryonic 
development, immune response, angiogenesis, and 
cancer [42-45]. Previous studies have shown that 
CD146 defines a functional subset of progenitor cell 
populations and exhibit higher developmental 
potentials [27, 46-47]. In vivo, CD146+ cells surround 
endothelial cells populating the vascular intima. With 
specific adhesion and migration properties, CD146+ 
cells can regulate blood vessel stability/integrity as 
well as the proliferation and motility of adjacent 
endothelial cells [48]. Both in vitro and in vivo studies 
provided evidence that CD146+ perivascular cells, as 
constituents of MSCs, and play a critical role during 
wound healing [49]. For example, increased number 
of CD146+ cells by activation of PDGF-BB/ PDGFRβ 
signaling pathway has been reported during wound 
healing in vivo [50]. CD146+ cells have also been 
shown to promote wound healing by secreting high 
levels of cytokines such as KGF, vascular endothelial 
growth factor (VEGF), heparin binding-epidermal 
growth factor (HB-EGF) and basic-fibroblast growth 
factor (bFGF) [51]. CD146+ cells isolated from human 
lipoaspirate showed immunomodulatory effect 
during bone formation [52]. In another study, CD146+ 
cells have been shown to induce increased cord 
formation [53]. In a degenerated intervertebral disc 
model, CD146+ MSCs showed greater migration 
potential for re-population [54]. However, the role of 
CD146+ cells as a seed cell type in cartilage tissue 
engineering is unclear.  
In this study, a CD146+ subpopulation of 
hADSCs was selected, and applied for cartilage repair 
as evidence from both in vitro and in vivo experiments 
supports its role in cartilage repair. The expressions of 
MSC related surface markers were almost unchanged 
after the enrichment. Pericytes as progenitor cells 
ubiquitously express surface markers such as NG2, 
PDGFR-β, and RGS5 in almost all organs [27, 55]. 
Consistent with previous reports, the CD146+ 
population from hADSCs expressed high levels of 
other pericyte markers, was distinct from hADSCs, 
and maintained their progenitor cell character. 
Immunogenicity affects the outcome of cell 
transplantation. MSCs can avoid allogeneic rejection, 
prolong graft survival, and induce tolerance in 
humans and in animal models. When CD146+ cells 
were sorted from human adipose tissue for bone 
formation in mice, no immunological rejection was 
observed [52]. MHC class II proteins are potent 
alloantigens. Under non-inflammatory conditions, 
human MSCs are MHC-II negative, supporting a role 
for MSC in having reduced immunogenicity through 
the control of alloantigen expression [56-60]. The 
expression of MHC-I in the CD146+ subpopulation is 
significantly lower than in hADSCs with no MHC-II 
expression, supporting a role for the CD146+ 
subpopulation with reduced immunogenicity 
through the control of alloantigen expression. 
Collectively, the CD146+ population has immune 
characteristics to avoid allogeneic rejection. 
Previous studies found that CD146 was 
associated with proliferation and expressed at high 
levels in nearly all clonal MSCs, while only a minority 
of nonclonal MSCs expressed this marker [31]. In this 
study, we observed high proliferation rate, cell 
viability, and low apoptosis verifying the cell survival 
capability of CD146+ cells, and supporting their 
suitability for transplantation. It was important to 
elucidate the characteristic features of CD146+ cells at 
the molecular level. Our microarray data highlighted 
a variety of functions of CD146+ cells in chemotaxis, 
wound healing, blood vessels, and inflammatory 
processes, confirming that the CD146+ population is 
functionally distinct from the hADSCs.  
Cartilage defects typically lead to posttraumatic 
inflammation and represent a significant challenge in 
cartilage repair [61]. It has been shown that MSCs can 
promote tissue repair by modulating inflammation 
[62]. In vitro, both gene and protein results revealed a 
differential expression profile of inflammation related 
cytokines between CD146+ cells and hADSCs. To 
investigate the specific cellular functions in the 
cartilage microenvironment in vivo, we injected 
CD146+ cells into the joint cavity. In the defect area, 
CD146+ cells did not lead to higher expression levels 
of IL-6 compared with hADSCs. This result is 
consistent with a previous report showing that a 
CD146+ subpopulation from human umbilical cord 
cells provided an anti-inflammatory protective 
microenvironment by suppressing IL-6 [34]. Another 
study also reported that CD146+ cell implantation 
reduced Ly-6G+ and F4/80+ cell infiltration in bone 
[52]. Thus, CD146+ population after enrichment plays 
a better role in modulating inflammation. 
The clinical applications of MSCs is often limited 
by their poor viability at the site of injury caused by 
the unfavorable microenvironment and to anoikis 
driven by the loss of cell adhesion [63]. To increase the 
viability of cells, we fabricated a cell ACECM scaffold 
composites to create a proper microenvironment for 
cell adhesion. For long-term cartilage regeneration, 
ACECM is the best biomaterial to mimic native 
cartilage and drive tissue homeostasis and 
regeneration because of the presence of bioactive 
molecules [64]. Also, ACECM is biodegradable and 
does not elicit adverse immune responses [64]. In this 
study, several findings supported good 
biocompatibility of cell ACECM scaffold composites. 





First, SEM images showed the loose and porous 
structure of ACECM that is suitable for cell adhesion. 
ADSCs and CD146+ cells were located on the inner 
wall of pores, maintained their phenotype, and 
functioned normally after culturing. Second, CD146+ 
cells and ADSCs proliferated and grew well in the 
three-dimensional porous scaffold, and the most 
viable cells exhibited a uniform distribution. Third, 
when the degradability of the cell-scaffold composites 
in vivo was tested by subcutaneous implantation in 
rabbits, they displayed good biocompatibility without 
any visible foreign body reaction. Finally, CD146+ 
subpopulation survived even 4 weeks after 
implantation confirming that ACECM scaffold 
created a proper microenvironment for cell adhesion. 
The lower number of inflammatory cells confirmed 
that the CD146+ cells caused a more significant 
reduction in subcutaneous inflammation than the 
more heterogeneous hADSCs. These results were 
consistent with the previous finding that CD146+ cells 
combined with collagen scaffold did not induce an 
early inflammatory infiltrate during bone formation 
[52]. 
In the rabbit implantation experiment, the 
outcome observed in the CD146+ subpopulation & 
ACECM scaffold composite implanted group was 
superior to all other groups as confirmed by imaging, 
macroscopic observation, and histological 
examination. The regenerative capacity of tissues 
depends on the degree of the inflammatory response 
[65]. We hypothesized that CD146+ subpopulation 
would play a superior role in inhibiting inflammation 
and promoting long term outcome. ACECM can 
stimulate growth and proliferation, and ensure the 
normal functioning of CD146+ subpopulation. 
Enhanced proliferation of the CD146+ subpopulation 
can offset the dysfunction caused by the insufficient 
number of cells. Also, direct differentiation of MSCs 
into chondrocytes is one of the key factors for 
cartilage repair. In this context, the differentiation 
ability of the CD146+ subpopulation has been 
demonstrated in previous studies [27, 66-68]. CD146+ 
cells can directly differentiate into chondrocytes and 
promote cartilage repair. However, CD146 is not a 
specific chondrogenesis marker, although some 
studies have shown that CD146+ subset has better 
chondrogenic differentiation ability [67]. It is of note 
that CD146- subset can also differentiate into 
chondrocytes [54]. CD146- cells are also heterogeneity 
and contain progenitors cells of MSC. For example, 
CD34+ cells, resides in the outmost layer of blood 
vessels, also natively express MSC markers and give 
rise in culture to progenitors cells of MSC [69]. The 
regulation of chondrogenic differentiation in CD146+ 
and CD146- cells remains to be further investigated. 
The quantity and stability of cells are important 
factors that affect subpopulation-based therapy. 
CD146+ cells sorted from fetal and adult muscle, 
midterm placenta, fetal skin, fetal pancreas, bone 
marrow, and adipose tissue can retain the phenotype, 
exhibit osteogenic, chondrogenic, and adipogenic 
potentials and express MSC and pericyte markers 
[27]. For example, muscle-derived CD146+ cells stably 
expressed pericyte markers such as NG2, CD146, and 
α-SMA after 4, 8, or 14 passages [27]. CD146+ cells 
from mesenchymoangioblast can be cultured in the 
presence of platelet-derived growth factor (PDGF)-BB 
for up to 12 passages with gradual senescence 
observed during 8–12 passages [70]. In our study, we 
used cells for in vivo cartilage repair without long term 
culture in vitro. Compared with bone marrow MSCs, 
large numbers of ADSCs can be obtained from 
lipoaspirate in one attempt with less pain. In the rat 
model, CD146+ cells were injected into the joint cavity 
immediately after MACS enrichment without in vitro 
culture. In the rabbit model, CD146+ cells were 
cultured 3 days before in vivo implantation. In future 
clinical applications, sufficient numbers of CD146+ 
subpopulation can be obtained without requiring 
serial sub-culturing in vitro. Thus, subpopulation-ased 
strategy in this study is more feasible for clinical 
translation. Another important issue that needs to be 
explored in the future is the variability of CD146+ cells 
between donors to enable selection of the proper 
subpopulation for therapy. 
Conclusions 
Our study highlights the importance of a 
subpopulation-based MSCs therapy in regenerative 
medicine. Although it has long been known that 
MSCs are heterogeneous and subpopulations vary 
functionally, the precise roles of different 
subpopulations in cartilage tissue repair has remained 
elusive. Our ultimate goal is to optimize cartilage 
structure and function utilizing specific properties of 
MSC subtypes and make tissue engineering more 
effective. Thus, uncovering the functional 
characteristics of specific subtypes of MSCs is a new 
direction for cell-based tissue engineering research 
and can potentially further the development of 
precision medicine. 
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